China SXT Pharmaceuticals, Inc. Accounts Receivable
China SXT Pharmaceuticals, Inc. (SXTC) had Accounts Receivable of $931.57 thousand as of 2026-03-31, per its 20-F filed 2026-07-01.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-07-01
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $931.57K.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $1.34M.
- 2025-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $1.30M.
- 2024-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $1.66M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-03-31 | $931.57K 20-F · filed 2026-07-01 |
| 2025-09-30 | $1.34M 6-K · filed 2025-12-31 |
| 2025-03-31 | $1.30M 20-F · filed 2026-07-01 |
| 2024-09-30 | $1.66M 6-K · filed 2025-03-28 |
| 2024-03-31 | $1.31M 20-F · filed 2025-07-31 |
| 2023-09-30 | $1.31M 6-K · filed 2024-04-05 |
| 2023-03-31 | $1.34M 20-F · filed 2024-08-13 |
| 2022-09-30 | $3.32M 6-K · filed 2023-02-24 |
| 2022-03-31 | $3.33M 20-F · filed 2023-07-31 |
| 2021-09-30 | $3.88M 6-K · filed 2022-01-14 |
| 2021-03-31 | $4.51M 20-F/A · filed 2023-05-19 |
| 2020-09-30 | $5.58M 6-K · filed 2021-01-28 |
| 2020-03-31 | $3.82M 20-F · filed 2021-08-13 |
| 2019-09-30 | $4.57M 6-K/A · filed 2020-05-22 |
| 2019-03-31 | $4.18M 20-F · filed 2020-07-31 |
| 2018-03-31 | $2.60M 20-F · filed 2019-08-15 |